Patents by Inventor Brian Higgins

Brian Higgins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220280370
    Abstract: Methods, systems, and apparatuses are described that are configured for determining a path of an apparatus, engaging a motor to cause the apparatus to proceed along the path, receiving one or more of LIDAR data, ultrasonic data, or optical flow data, determining, based on one or more of the LIDAR data, the ultrasonic data, or the optical flow data, one or more objects in the path of the apparatus, and engaging the motor to cause the apparatus to avoid the one or more objects.
    Type: Application
    Filed: September 28, 2020
    Publication date: September 8, 2022
    Inventor: Brian Higgins
  • Patent number: 11425513
    Abstract: A suspension assembly for a hearing aid receiver is described in which the receiver is contained within a receiver can. A cover assembly may be provided for covering the open top end of the receiver can and for containing the receiver's spout when the receiver is mounted within the receiver can. To dampen or reduce the transmission of receiver vibrations within the receiver can, a spout seal and corner bumpers may also be provided.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 23, 2022
    Assignee: Starkey Laboratories, Inc.
    Inventors: Sidney A. Higgins, Brian Dobson
  • Patent number: 11382892
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 12, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Brian Higgins, Gwen Nichols, Lin-Chi Chen
  • Publication number: 20220124107
    Abstract: A system and method for implementing an extensible webhook service of a system of record includes receiving API-based webhook criteria for configuring an extensible webhook control data structure within a system of record; encoding the extensible webhook control data structure based on the API-based webhook criteria, wherein the encoding includes: (A) setting a webhook launching condition defining a custom API call that, when received, causes (i) an automatic creation of a payload of data from data sources within a system of record and (ii) an execution of a webhook operation; and (B) setting the webhook operation that identifies a web-based destination for the payload of data and that, when executed, causes an automatic transmission of the payload of data from the system of record to the web-based destination; wherein the extensible webhook control data structure, once encoded, automatically controls an interchange of data between the system of record and distinct external entities.
    Type: Application
    Filed: October 8, 2021
    Publication date: April 21, 2022
    Inventor: Brian Higgins
  • Publication number: 20220031726
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 3, 2022
    Inventors: Brian Higgins, Kathryn E. Packman, Gwen Nichols
  • Publication number: 20210069149
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 11, 2021
    Inventors: Kellie Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Publication number: 20200253999
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 13, 2020
    Inventors: Brian Higgins, Kathryn E. Packman, Gwen Nichols
  • Publication number: 20200085788
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: July 23, 2019
    Publication date: March 19, 2020
    Inventors: Brian Higgins, Gwen Nichols, Lin-Chi Chen
  • Publication number: 20190328708
    Abstract: There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 31, 2019
    Inventors: Kelli Glenn, Brian Higgins, Gwen Nichols, Kathryn Packman
  • Publication number: 20190270717
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Application
    Filed: September 14, 2018
    Publication date: September 5, 2019
    Applicant: MICROMIDAS, INC.
    Inventors: Makoto Nathanael MASUNO, John BISSELL, II, Ryan L. SMITH, Brian HIGGINS, Alex B. WOOD
  • Patent number: 10119265
    Abstract: A building frame connector for connecting beams to columns to create a building frame. The building frame connector includes a pin member and plurality of fins mounted on said pin member for rotation relative to said pin. The pin may be in alignment with the column, and the fins allow connection of the beams to the columns. The fins may be disposed to rotate relative to said pin member about a longitudinal axis of the pin. In one embodiment the pin member may have an outer diameter and the fins have a collar with an inner diameter is greater than said outer diameter of said pin allowing for the collars to rotate about the pin member. The present building frame connector may also include at least one coupling member coupled to the pin member, wherein the coupling member facilitates the connection of the building frame connector to a building column.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: November 6, 2018
    Assignee: Carbon Development Services, LLC
    Inventor: Brian Higgins
  • Patent number: 10093638
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 9, 2018
    Assignee: MICROMIDAS, INC.
    Inventors: Makoto Nathanael Masuno, John Bissell, II, Ryan L. Smith, Brian Higgins, Alex B. Wood
  • Patent number: 9956243
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction such as, for example: and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 1, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Gwen Nichols, Kathryn E. Packman
  • Publication number: 20180044311
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Application
    Filed: March 24, 2017
    Publication date: February 15, 2018
    Applicant: MICROMIDAS, INC.
    Inventors: Makoto Nathanael MASUNO, John BISSELL, II, Ryan L. SMITH, Brian HIGGINS, Alex B. WOOD
  • Publication number: 20170130444
    Abstract: A building frame connector for connecting beams to columns to create a building frame. The building frame connector includes a pin member and plurality of fins mounted on said pin member for rotation relative to said pin. The pin may be in alignment with the column, and the fins allow connection of the beams to the columns The fins may be disposed to rotate relative to said pin member about a longitudinal axis of the pin. In one embodiment the pin member may have an outer diameter and the fins have a collar with an inner diameter is greater than said outer diameter of said pin allowing for the collars to rotate about the pin member. The present building frame connector may also include at least one coupling member coupled to the pin member, wherein the coupling member facilitates the connection of the building frame connector to a building column.
    Type: Application
    Filed: October 11, 2016
    Publication date: May 11, 2017
    Inventor: Brian Higgins
  • Patent number: 9637463
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 2, 2017
    Assignee: MICROMIDAS, INC.
    Inventors: Makoto Nathanael Masuno, John Bissell, II, Ryan L. Smith, Brian Higgins, Alex B. Wood
  • Patent number: 9486445
    Abstract: Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: November 8, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Brian Higgins, Kenneth Kolinsky, Gwen Nichols, Kathryn Packman, Fei Su
  • Publication number: 20160303158
    Abstract: The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
    Type: Application
    Filed: December 1, 2014
    Publication date: October 20, 2016
    Inventors: Brian Higgins, Kathryn E. Packman, Gwen Nichols
  • Publication number: 20160256529
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 8, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Kapil DHINGRA, Brian HIGGINS, Kenneth KOLINSKY, Richard J. LEE, Brian LESTINI, Kathryn PACKMAN, Fei SU
  • Publication number: 20160168107
    Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.
    Type: Application
    Filed: July 21, 2015
    Publication date: June 16, 2016
    Applicant: MICROMIDAS, INC.
    Inventors: Makoto Nathanael MASUNO, John BISSELL, II, Ryan L. SMITH, Brian HIGGINS, Alex B. WOOD